ZURICH, SWITZERLAND - EQS Newswire - March 11, 2020 - Xlife Sciences AG tests a new therapy for the treatment of pneumonia caused by coronavirus in cooperation with the Institute of Virology and Immunology (IVI) of the Vetsuisse Faculty of the University of Bern in Switzerland. Advantages of the therapy are a fundamentally better biovariability and a broad target diversity. The necessary documents have successfully been submitted.

The issuer is solely responsible for the content of this announcement.

Talk to Media OutReach today

Let Media OutReach help you achieve your communication goals. Send an email to info@media-outreach.com or click below. You will receive a response within 24 hours.

Contact us now